Clopidogrel
Product Images NDC 50436-9986

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Clopidogrel (NDC 50436-9986). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Clopidogrel Fig1)

A horizontal bar chart depicting the effect of proton pump inhibitors (PPIs) on exposure to Clopidogrel active metabolite AUC. It compares changes relative to Clopidogrel bisulfate administered alone, showing data for Dexlansoprazole 60 mg, Lansoprazole 30 mg, Pantoprazole 80 mg, and Omeprazole 80 mg, with mean values and 90% confidence intervals.*

FDA Label Image

Figure 2: Cardiovascular Death, Myocardial Infarction, And Stroke In The Cure Study (Clopidogrel Fig2)

A line graph comparing cumulative event rates (%) of cardiovascular death, myocardial infarction, and stroke over 12 months of follow-up between placebo (+ aspirin) and Clopidogrel Bisulfate (+ aspirin) groups. The graph shows lower event rates in the Clopidogrel Bisulfate group with a p-value indicating statistical significance.*

FDA Label Image

Figure-3 (Clopidogrel Fig3)

A forest plot chart comparing the hazard ratios with 95% confidence intervals for Clopidogrel Bisulfate versus placebo across multiple subgroups, including age, gender, race, elevated cardiac enzymes, diabetes, previous MI, previous stroke, anticoagulant use, aspirin dosage, use of GPIIb/IIIa antagonists, beta-blockers, and ACE inhibitors. The chart visually indicates which subgroups favor Clopidogrel or placebo in the context of these variables.*

FDA Label Image

Figure 4: Cumulative Event Rates For Death In The Commit Study (Clopidogrel Fig4)

This chart depicts cumulative percentage of deaths before first discharge over days since randomization (up to 28 days) comparing Clopidogrel versus placebo. The curve shows lower death rates with Clopidogrel (7.5%) compared to placebo (8.1%), indicating a 7% proportional risk reduction (p = 0.03).*

FDA Label Image

Figure 5: Cumulative Event Rates For The Combined Endpoint Re-infarction, Stroke Or Death In The Commit Study (Clopidogrel Fig5)

A Kaplan-Meier curve chart showing the percentage of subjects experiencing death, re-infarction, or stroke before first discharge over 28 days since randomization. The chart compares placebo and Clopidogrel groups, indicating a lower event rate for Clopidogrel. Event counts and proportional risk reduction data are annotated on the chart.*

FDA Label Image

Figure 6: Effects Of Adding Clopidogrel Bisulfate To Aspirin On The Combined Primary Endpoint Across Baseline And Concomitant Medication Subgroups For The Commit Study (Clopidogrel Fig6)

A forest plot chart comparing odds ratios for Clopidogrel Bisulfate versus placebo across various subgroups such as gender, age, hours since onset, systolic blood pressure, heart rate, and fibrinolytic agent administration. The chart displays odds ratios with 99% confidence intervals for each subgroup and overall results.*

FDA Label Image

Figure 7: Fatal Or Non-fatal Vascular Events In The Caprie Study (Clopidogrel Fig7)

A line chart titled 'Fatal or Non-Fatal Vascular Events' showing cumulative event rate percentages over 36 months of follow-up. Two lines compare aspirin and clopidogrel bisulfate event rates, with aspirin showing a slightly higher cumulative event rate. A p-value of 0.045 is noted at the bottom right.*

FDA Label Image

Figure 8: Hazard Ratio And 95% Ci By Baseline Subgroups In The Caprie Study (Clopidogrel Fig8)

A hazard ratio plot comparing Clopidogrel Bisulfate and Aspirin outcomes across qualifying conditions: stroke, myocardial infarction (MI), and peripheral artery disease (PAD). The graph displays sample sizes and event percentages for each treatment group, with confidence intervals indicating favorability towards either Clopidogrel Bisulfate or Aspirin.*

FDA Label Image

Chemical Structure (Clopidogrel Str)

Chemical structure of Clopidogrel bisulfate showing molecular arrangement including a thiophene ring, chlorine-substituted aromatic ring, and carboxylate functional group.*

FDA Label Image

Label Image (Lbl504369986)

Clopidogrel Bisulfate film-coated tablets, 75 mg strength, presented in a unit dose packaging containing 30 tablets. The label includes manufacturing information by Aurobindo and is marked as distributed by Unit Dose Services, LLC, FL 33179. The label shows storage instructions (20-25°C) and warnings to keep out of reach of children.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.